ERBB2 and inflammatory breast carcinoma: A single-agent lapatinib in HER2+ IBC patients who had disease progression resulted in a 39% overall response rate and a 20.9-week median duration of response (ClinicalTrials.gov Identifier: NCT00105950; A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer; Table 1) [49].